Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review

Poku, Edith; Brazier, John; Carlton, Jill; Ferreira, Alberto

doi:10.1186/1471-2415-13-74

Table 3 Utility estimates according to visual acuity in the better-seeing eye

From: Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review

Study reference	HSUV instrument	Mean utility (SD)	Visual acuity
			20/20 to 20/25	20/30 to 20/40	20/50 to 20/100	≤ 20/200
			Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
			N	N	N	N
Studies with visual acuity levels based on relevant conditions
*DR studies*
Lloyd et al. [24]	EQ-5D	NR	0.75(0.23)	0.50(0.30)	0.68(0.29)	0.53(0.47)
Lloyd et al. [24]	EQ-5D	NR	68	13	10	7
						0.34(0.36)^a
						3
Lloyd et al. [24]	HUI3	NR	0.78(0.22)	0.30(0.38)	0.61(0.35)	0.52(0.50)
Lloyd et al. [24]	HUI3	NR	68	13	10	7
						0.37(0.00)^a
						3
Brown et al. [16]	TTO	0.79	0.86(0.17)	0.80(0.19)	0.77(0.18)	0.61(0.19)
Brown et al. [16]	TTO	(0.2)	72	130	95	36
Sharma et al. [27]		0.79	0.88(0.19)	0.79(0.22)	0.73(0.26)	0.73(0.22)
Sharma et al. [27]		(0.2)	NR	NR	NR	NR
						0.48(0.47)^a
						NR
*AMD studies*
Aspinall et al. [19]^c	TTO	0.81	0.93	0.86	0.74	0.68
						0.76^b
Brown et al. [16]		0.74(0.23)	0.84(0.21)	0.80(0.19)	0.71(0.22)	0.59(0.22)
Brown et al. [16]			60	65	57	65
Lee et al. [23]	SG^d		0.89(0.23)	0.76(0.30)	NR	NR
Lee et al. [23]	SG^d		23	21	NR	NR
Lee et al. [23]	SG^e		0.86(0.24)	0.39(0.37)	NR	NR
Lee et al. [23]	SG^e		23	21	NR	NR
Studies with visual acuity levels not based on relevant conditions ^f
Brown [30]	TTO		0.89(0.17)	0.82(0.21)	0.74(0.21)	0.62(0.20)
Brown [30]	TTO		82	98	89	38
						0.46 (0.29)^a
						18
Brown et al. [32]			0.88(0.15)	0.81(0.21)	0.72(0.21)	0.61(0.19)
Brown et al. [32]			127	218	83	72
Shah et al. [33]			0.88(0.19)	0.90(0.14)	0.76(0.23)
Shah et al. [33]			71	43	22
Sharma et al. [34]			0.91(0.15)	0.80(0.21)	0.71(0.21)	0.62(0.20)
Sharma et al. [34]			75	136	58	37
						0.473(0.32)
						17^a
Brown [30]	SG		0.94 (0.12)	0.90(0.19)	0.81(0.21)	0.74(0.21)
Brown [30]	SG		82	98	89	38
						0.60(0.30)
						18^a
Sharma et al. [34]			0.95(0.11)	0.90(0.17)	0.77(0.28)	0.74(0.22)
Sharma et al. [34]			75	136	58	37
						0.60(0.32)
						17^a

Abbreviations: AMD age-related macular degeneration, DR diabetic retinopathy, EQ-5D EuroQol values, HUI3 Health utilities index Mark 3 values, NR not reported, SD standard deviation, SG standard gamble values, TTO time-trade-off estimates.
^aValues for levels corresponding to counting fingers to no light perception.
^bValues for levels corresponding to counting fingers to light perception.
^cVA level based on binocular distance vision and not VA in the better seeing-eye. Authors stated that the difference between the two measures was not significant. SD not calculated because of missing data. Figures shown were derived from the nearest equivalent Snellen categories of VA in the relevant article.
^dStandard gamble values based on the policy scale; anchors used were perfect vision/death.
^eStandard gamble values based on the vision scale; anchors used were perfect vision/unilateral blindness.
^fRelevant populations refers to patients with diabetic retinopathy and age-related macular degeneration. Macular oedema was not described in full, so it is unclear if patients had diabetic macular oedema.

Back to article page

ISSN: 1471-2415

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Ophthalmology

Contact us